GA
ATOS icon

Geneva Advisors’s Atossa Therapeutics ATOS Stock Holding History

Geneva Advisors’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-4
Closed -$3K – 725
2016
Q1 		$3K Hold
4
– – ﹤0.01% 703
2015
Q4 		$3K Hold
4
– – ﹤0.01% 654
2015
Q3 		$8K Hold
4
– – ﹤0.01% 626
2015
Q2 		$11K Buy
+4
New +$16K ﹤0.01% 677

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GBBWRPM
Genovese Burford & Brothers Wealth & Retirement Plan Management Sacramento, California $400M AUM 14.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Geneva Advisors's ATOS Position: Q2 2016 in Review

Geneva Advisors sold out of Atossa Therapeutics (ATOS) in Q2 2016, closing a stake of 4 shares — an estimated $3K sold.

Geneva Advisors first reported a position in ATOS in Q2 2015 and held it in 4 quarters. The position peaked at $11K in Q2 2015. 14 funds tracked by Wall St. Rank hold ATOS as of Q2 2016.

  • Geneva Advisors reported no remaining Atossa Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Geneva Advisors sold 4 Atossa Therapeutics shares in Q2 2016, an estimated $3K.
  • Geneva Advisors first reported a position in Atossa Therapeutics in Q2 2015 and held it in 4 quarters.
  • Geneva Advisors's Atossa Therapeutics position peaked at $11K in Q2 2015.
  • 14 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2016.

Based on Geneva Advisors's 13F filing for Q2 2016, filed 8 Aug 2016.